drugset / Trial / NCT07670702

An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD

NCT07670702

Phase 3 Enrolling by invitation 300 enrolled Transcend Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial. Each participant will be able to receive up to three Treatment Courses over the duration of the study (up to 48 weeks). Each Treatment Course includes 4 dosing sessions, spaced one week apart.

Timeline

Start
2026-06
Primary completion
2028-12
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylone Other / unclassified Oral